Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06466187 · ClinicalTrials.gov registry record · Phase 1

A Study of SGN-MesoC2 in Advanced Solid Tumors

A Phase 1 study of Carcinoma, Non-Small Cell Lung and Pancreatic Adenocarcinoma, sponsored by Seagen, a wholly owned subsidiary of Pfizer.

Active
Registry status
Phase 1
Development phase
19
Enrollment target
20
Study locations

NCT06466187: Active Phase 1 study of Carcinoma, Non-Small Cell Lung and Pancreatic Adenocarcinoma, sponsored by Seagen, a wholly owned subsidiary of Pfizer.

NCT06466187 is a Phase 1 study of Carcinoma, Non-Small Cell Lung and Pancreatic Adenocarcinoma that is active but no longer recruiting, run by Seagen, a wholly owned subsidiary of Pfizer. The registered enrollment target is 19 participants, below the 324-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06466187, a Phase 1 study of Carcinoma, Non-Small Cell Lung and Pancreatic Adenocarcinoma, is active but no longer recruiting, sponsored by Seagen, a wholly owned subsidiary of Pfizer.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
19 participants
Enrollment target
20
Study locations

Study Summary

This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts of your body, it's called metastatic. When a cancer has gotten so big it can't easily be removed or has spread to other parts of the body, it is called unresectable. These types of cancer are harder to treat. Patients in this study must have cancer that has come back or did not get better with treatment. Patients must have a solid tumor cancer that can't be treated with standard of care drugs. This clinical trial uses an experimental drug called PF-08052666/SGN-MesoC2. PF-08052666/SGN-MesoC2 is a type of antibody-drug conjugate (ADC). ADCs are designed to stick to cancer cells and kill them. They may also stick to some normal cells. This study will have 3 parts. Part A and Part B of the study will find out how much PF-08052666/SGN-MesoC2 should be given to participants. Part C will use the information from Parts A and B to see if PF-08052666/SGN-MesoC2 is safe and if it works to treat solid tumor cancers.

Primary Outcome

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Conditions Studied

Carcinoma, Non-Small Cell Lung Pancreatic Adenocarcinoma Colorectal Neoplasms Mesothelioma Ovarian Neoplasms Other Solid Tumors Endometrial

Interventions

  • DRUG PF-08052666

Study Locations (20)

Kansas

  • The University of Kansas Clinical Research Center - Fairway
  • The University of Kansas Hospital Cambridge North Tower A - Kansas City
  • The University of Kansas Hospital - Kansas City
  • The University of Kansas Medical Center Medical Office Building - Kansas City
  • The University of Kansas Cancer Center - Indian Creek Campus - Overland Park
  • The University of Kansas Cancer Center - Westwood - Westwood
  • The University of Kansas Cancer Center, Investigational Drug Services - Westwood

Alabama

  • University of Alabama at Birmingham - Birmingham
  • The University of Alabama at Birmingham - Birmingham
  • University of Alabama at Birmingham - Birmingham
  • The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham - Birmingham

Tennessee

  • Sarah Cannon Research Institute - Pharmacy - Nashville
  • SCRI Oncology Partners - Nashville

Utah

  • START Mountain Region, LLC - Salt Lake City
  • START Mountain Region - West Valley City

Ontario

  • University Health Network - Toronto
  • University Health Network, Princess Margaret Cancer Centre - Toronto

North Carolina

  • Atrium Health Wake Forest Baptist - Winston-Salem

Texas

  • START San Antonio, LLC - San Antonio

Quebec

  • The Research Institute of the McGill University Health Centre - Montreal

Trial Details

FieldValue
Enrollment Target 19 participants
Start Date 2024-08-02
Est. Completion 2029-05-01
Phase Phase 1
Seagen, a wholly owned subsidiary of Pfizer

28 total trials

What the registry record for NCT06466187 still lists

NCT06466187 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 324-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (94% lower).

The record links to 7 conditions, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 1 intervention - of which PF-08052666 is the first listed.

NCT06466187 names 20 study sites across 8 states, led by Kansas, Alabama, Tennessee.

Frequently Asked Questions

What is clinical trial NCT06466187 about?

NCT06466187 is a clinical study titled "A Study of SGN-MesoC2 in Advanced Solid Tumors". This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts o...

What is the current status of trial NCT06466187?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2024-08-02. Estimated completion is 2029-05-01.

What conditions does trial NCT06466187 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung, Pancreatic Adenocarcinoma, Colorectal Neoplasms, Mesothelioma, Ovarian Neoplasms.

What interventions are being tested in trial NCT06466187?

The interventions under investigation include: PF-08052666 (DRUG).

Who is sponsoring clinical trial NCT06466187?

This trial is sponsored by Seagen, a wholly owned subsidiary of Pfizer, which has 28 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06466187 being conducted?

This trial has 20 study locations across Alabama, Kansas, North Carolina, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06466187's enrollment target sits among peer trials

19 118th of 130 higher than 12 of 130 other Carcinoma, Non-Small Cell Lung trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03207464 · 19 participants · Phase 1

    Molecular Imaging of NET Using [C-11]MRB-PET in MS

  • NCT04318717 · 19 participants · Phase 2

    Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma

  • NCT05103904 · 19 participants · Phase 2

    Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

  • NCT05607407 · 19 participants · Phase 2

    Methimazole in Patients With Progressive Glioblastoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT06466187, the US trial registry maintained by the National Library of Medicine. NCT06466187 (small enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.